Shortage Of Blood Products Means Record Sales For China Biologic Products
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China Biologic Products announced record financial results for the quarter ending Sept. 30, despite declining sales volumes
You may also be interested in...
Therapeutic Immunity? Plasma, Immunoglobulin Therapies Shield CSL From Global Financial Crisis
PERTH, Australia - Australian-headquartered CSL Limited has not been affected by the global financial crisis CEO Brian McNamee told analysts Feb. 18 during a half-year earnings call. Australia's financial year begins July 1 and ends June 30
Therapeutic Immunity? Plasma, Immunoglobulin Therapies Shield CSL From Global Financial Crisis
PERTH, Australia - Australian-headquartered CSL Limited has not been affected by the global financial crisis CEO Brian McNamee told analysts Feb. 18 during a half-year earnings call. Australia's financial year begins July 1 and ends June 30
China Biologic Starts Selling Human Immunoglobulin To Neighboring India, Scans Globe For New Markets
BEIJING - China Biologic Products has signed a unique deal to supply India with plasma-based biopharmaceuticals, and is scanning the global market for other potential importers, according to company executives